// App-Quantinova.ai

276 : Outcomes of first-line (1L) immuno-oncology (IO) combination therapies in metastatic renal cell carcinoma (mRCC): Results from the International mRCC Database Consortium (IMDC).

Researchers

Presenter

  • Chun Loo Gan

Principal Investigators

  • J Connor Wells

  • Andrew Lachlan Schmidt

  • Ziad Bakouny

  • Bernadett Szabados

  • Francis Parnis

  • Shirley Wong

  • Jae-Lyun Lee

  • Guillermo de Velasco

  • Sumanta K. Pal

  • Ian D. Davis

  • Ravindran Kanesvaran

  • Lori Wood

  • Christian K. Kollmannsberger

  • Rana R. McKay

  • Benoit Beuselinck

  • Frede Donskov

  • Toni K. Choueiri

  • Daniel Yick Chin Heng

Medical Centers

  • Tom Baker Cancer Center - University of Calgary, Calgary, AB, Canada

  • Ottawa Hospital Cancer Center, University of Ottawa, Ottawa, ON, Canada

  • University of Calgary, Calgary, AB, Canada

  • Liz Plummer Cancer Centre, Cairns and Hinterland Hospital and Health Service, Cairns, QLD, Australia

  • Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, Boston, MA

  • Barts Cancer Institute, Queen Mary University of London, London, United Kingdom

  • University of Adelaide, Adelaide, Australia

  • Wetsern Health, Foostcray, Australia

  • Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea

  • Medical Oncology Department. Hospital 12 de Octubre, Madrid, Spain

  • Eastern Health Clinical School, Monash University, Box Hill, VIC, Australia

  • National Cancer Centre Singapore, Singapore, Singapore

  • Dalhousie University, Halifax, Nova Scotia, Canada.

  • BC Cancer - Vancouver Centre, Vancouver, BC, Canada

  • University of California, San Diego, Moores Cancer Center, La Jolla, CA

  • Leuven Cancer Institute, Universitaire Ziekenhuizen, Leuven, Belgium

  • Aarhus University Hospital, Aarhus, Denmark

  • Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA

Locations

  • Canada

  • Australia

  • United States

  • United Kingdom

  • Republic of South Korea

  • Spain

  • Singapore

  • Belgium

  • Denmark

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Nephrology

Disease

  • Metastatic Renal Cell Cancer

Biomarkers

  • N/A

Drug/Treatment

  • Pembrolizumab

  • Cabozantinib

  • Nivolumab

  • Inlyta

  • Avelumab

  • Techniclone TNT

Outcome

  • N/A

Study Design

  • Multinational

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved